Generic imatinib vs Glivec for newly diagnosed CML
Part of Blood & lymphatic, Cancer clinical trials.
This trial studies whether a generic version of imatinib (Carcemia®) works as well and is as safe as Glivec® in real-life care for people newly diagnosed with chronic phase chronic myeloid leukemia (CML). It may help confirm that the generic option is effective for controlling the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You were newly diagnosed with Philadelphia chromosome–positive (Ph+) CML in the chronic phase
- Your diagnosis must be confirmed within 3 months before enrolling
- Your liver blood tests (aminotransferases and bilirubin) must be no more than 2 times the normal upper limit
- Your kidney blood test (creatinine) must be no more than 1.5 times the normal upper limit
- You must be able to sign a consent form to join
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the drug asciminib for people newly diagnosed with chronic myeloid leukemia (CML) who have been on treatment for less than a month. It aims to see if early treatment with asciminib is safe and effective.
This study compares two different medicines for people with chronic myeloid leukemia (CML) whose current treatment with imatinib (Gleevec) has not worked well enough. It tests whether switching to dasatinib (Sprycel) or increasing the dose of imatinib to 600 mg helps get the disease under better control.
This study tests a targeted pill called asciminib for people newly diagnosed with chronic-phase CML. It aims to see if this drug is safe and effective as an early treatment option.
This trial tests an experimental drug called TGRX-678 for people with a specific, more advanced stage of chronic myeloid leukemia (CML) called 'accelerated phase.' It’s for patients whose cancer has stopped responding to or who couldn't tolerate earlier targeted therapies (tyrosine kinase inhibitors).
This study compares two oral medications, flumatinib and imatinib, to see which is more effective and safer for people newly diagnosed with chronic myeloid leukemia in its early phase. It aims to help doctors choose the best initial treatment.
This trial tests a new pill, asciminib, as the first treatment for people newly diagnosed with chronic myeloid leukemia (CML) in its early phase. The goal is to see if it can control the disease with fewer side effects than standard treatments.
Hear when a new Chronic Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.